D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
In a recent filing with the Securities and Exchange Commission, 180 Life Sciences Corp. disclosed the immediate resignation of its Chief Financial Officer (CFO), Omar Jimenez, on Monday.
The company, which specializes in pharmaceutical preparations and is based in Palo Alto, California, stated that Jimenez's departure was not due to any disagreements over the company's operations, policies, or practices.
Following the resignation, the company's Interim Chief Executive Officer (CEO), Blair Jordan, has taken on the additional role of principal financial and accounting officer on an interim basis. Jordan's background and other pertinent information were detailed in the company's proxy statement filed on November 12, 2024, which is incorporated by reference in the current report.
The company has confirmed that Jordan will not receive any extra compensation for assuming these additional responsibilities. 180 Life Sciences has yet to name a permanent replacement for the CFO position.
The information in this article is based on the company's statement in the SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.